Early IL-1 inhibition and long-term remission in childhood-onset Still's disease: a real-world cohort study - Takeaways - MDSpire

Early IL-1 inhibition and long-term remission in childhood-onset Still's disease: a real-world cohort study

  • By

  • Burcu Bozkaya Yücel

  • Seyda Dogantan

  • Semanur Ozdel

  • Özlem Aydoğ

  • June 15, 2026

  • 0 min

Share

  • 1

    Early IL-1 blockade in childhood-onset Still's disease leads to rapid disease control and high rates of treatment-free remission.

  • 2

    In a cohort of 18 patients, 94.4% received IL-1 inhibition as first-line therapy, with 66.7% achieving clinical inactive disease at 6 months.

  • 3

    Macrophage activation syndrome (MAS) occurred early in 44.4% of patients, but no recurrent episodes were noted during follow-up.

  • 4

    Biologic therapy was switched in 77.8% of patients, primarily due to treatment burden associated with daily injections.

  • 5

    The study supports early cytokine inhibition as a cornerstone of treat-to-target strategies in managing childhood-onset Still's disease.

Original Source(s)

Early IL-1 inhibition and long-term remission in childhood-onset Still's disease: a real-world cohort study

  • by Burcu Bozkaya Yücel, Seyda Dogantan, Semanur Ozdel, Özlem Aydoğ

  • June 15, 2026

Related Content

Case Report: Arthroscopic minimally invasive treatment of pediatric calcaneal fracture

Extent of the low-density line is associated with time to fracture in children with congenital anterolateral bowing of the tibia: a retrospective survival analysis

Identification and management of unrecognized femoral head epiphysiolysis: a case report